EMQN CIC is organising a ring trial study for genomic testing of prostate cancer samples in relation to eligibility for PARP inhibitor therapy, on behalf of AstraZeneca. The study will involve laboratories testing plasma samples for HRR genes variants associated with prostate cancer. This project is NOT an EQA scheme and there are no performance consequences.
Samples will be shipped in January 2021 (exact date TBC) and laboratories will be compensated by EMQN for taking part. The results of the ring trial will be published in a peer reviewed journal and all participants acknowledged as having contributed to the project.
If you are interested in taking part, then please complete our survey. This survey is designed to gather insights on current practices for HRRm testing in prostate cancer (including ctDNA testing using plasma) and receive expressions of interest to participate in this project. Please complete it to register your interest in participation. Applications close on the 31st October 2020 at 23:59 GMT.
N.B. completion of the survey does not guarantee participation as numbers will be limited to a maximum of 30 laboratories. EMQN and AstraZeneca will select laboratories based on the survey responses.